Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor

Background: The PRECISE-DAPT and PARIS risk scores (RSs) were recently developed to help clinicians at individualizing the optimal dual antiplatelet therapy duration (DAPT) after percutaneous coronary intervention (PCI). Nevertheless, external validation of these RSs it has not yet been performed in ACS (acute coronary syndrome) patients treated with prasugrel or ticagrelor in a real- world scenario. Methods: 4424 ACS patients who underwent PCI and survived to hospital discharge, from January 2012 to December 2016 at 12 European centers, were included. PRECISE-DAPT and PARIS bleeding RS, as well as PARIS ischemic RS, were computed, and their performance at predicting major bleeding (MB; BARC type 3 or 5) and ischemic events (MI and stent thrombosis) during follow up was compared. Results: After a median follow-up of 14 (interquartile range 12–20.9) months, 83 (1.88%) patients developed MB and 133 (3.0%) suffered an ischemic episode. PRECISE-DAPT performed better than PARIS bleeding RS (c-statistic = 0.653 vs. 0.593; p =.01 for comparison) in predicting MB. The RSs performance for MB prediction remained consistent in STEMI patients (c-statistic = 0.632 vs 0.575) or in those treated with prasugrel (c-statistic = 0.623 vs 0.586). PARIS ischemic RS exhibited superior discrimination in predicting ischemic complications compared to PRECISE-DAPT (c-statistic = 0.604 vs 0.568 p =.05 for comparison). Conclusion: Our data provide support to the use of PRECISE-DAPT in MB risk stratification for patients receiving DAPT in form of aspirin and prasugrel or ticagrelor whereas the PARIS ischemic RS has potential to complement the risk prediction with respect to ischemic events.

Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor / Bianco, Matteo; D'ascenzo, Fabrizio; Raposeiras Roubin, Sergio; Kinnaird, Tim; Peyracchia, Mattia; Ariza-Solé, Albert; Cerrato, Enrico; Manzano-Fernández, Sergio; Gravinese, Carol; Templin, Christian; Destefanis, Paola; Velicki, Lazar; Luciano, Alessia; Xanthopoulou, Ioanna; Rinaldi, Mauro; Rognoni, Andrea; Varbella, Ferdinando; Boccuzzi, Giacomo; Omedè, Pierluigi; Montabone, Andrea; Bernardi, Alessandro; Taha, Salma; Rossini, Roberta; Durante, Alessandro; Gili, Sebastiano; Magnani, Giulia; Autelli, Michele; Grosso, Alberto; Blanco, Pedro Flores; Giustetto, Carla; Garay, Alberto; Quadri, Giorgio; Queija, Berenice Caneiro; Srdanovic, Ilija; Paz, Rafael Cobas; Fernández, María Cespón; Pousa, Isabel Muñoz; Gallo, Diego; Morbiducci, Umberto; Dominguez-Rodriguez, Alberto; Lopez-Cuenca, Ángel; Cequier, Angel; Alexopoulos, Dimitrios; Iñiguez-Romo, Andres; Pozzi, Roberto; Assi, Emad Abu; Valgimigli, Marco.. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - ELETTRONICO. - 301(2020), pp. 200-206.

SFX


Titolo: Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor
Autori: 
D'ASCENZO, FABRIZIO
RINALDI, MAURO
GALLO, DIEGO
MORBIDUCCI, UMBERTO
mostra contributor esterni 
Data di pubblicazione: 2020
Rivista: 
INTERNATIONAL JOURNAL OF CARDIOLOGY  
Digital Object Identifier (DOI): http://dx.doi.org/10.1016/j.ijcard.2019.11.132
Appare nelle tipologie:1.1 Articolo in rivista

File in questo prodotto:
FileDescrizioneTipologiaLicenza 
Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor.pdf 2a Post-print versione editoriale / Version of RecordNon Pubblico - Accesso privato/ristrettoAdministrator   Richiedi una copia
IJC_2019_832_postprint.pdf 2. Post-print / Author's Accepted ManuscriptVisibile a tuttiVisualizza/Apri
Utilizza questo identificativo per citare o creare un link a questo documento:
http://hdl.handle.net/11583/2842964

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2021